These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32802413)

  • 1. M-protein based vaccine induces immunogenicity and protection from
    Mills JS; Jayashi Flores CM; Reynolds S; Wun C; Calcutt A; Baker SB; Murugappan S; Depelsenaire ACI; Dooley J; Fahey PV; Forster AH; Pandey M; Good MF
    NPJ Vaccines; 2020; 5(1):74. PubMed ID: 32802413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.
    Pandey M; Batzloff MR; Good MF
    PLoS One; 2009; 4(4):e5147. PubMed ID: 19340309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection.
    Batzloff MR; Hayman WA; Davies MR; Zeng M; Pruksakorn S; Brandt ER; Good MF
    J Infect Dis; 2003 May; 187(10):1598-608. PubMed ID: 12721940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.
    Campbell PT; Frost H; Smeesters PR; Kado J; Good MF; Batzloff M; Geard N; McVernon J; Steer A
    Vaccine; 2018 Nov; 36(50):7618-7624. PubMed ID: 30401621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
    Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: Author Correction: M-protein based vaccine induces immunogenicity and protection from
    Mills JS; Jayashi Flores CM; Reynolds S; Wun C; Calcutt A; Baker SB; Murugappan S; Depelsenaire ACI; Dooley J; Fahey PV; Forster AH; Pandey M; Good MF
    NPJ Vaccines; 2020; 5():80. PubMed ID: 32944294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Alum-Adjuvanted Peptide and Carbohydrate Conjugate Vaccine Candidates against Group A
    Rivera-Hernandez T; Carnathan DG; Richter J; Marchant P; Cork AJ; Elangovan G; Henningham A; Cole JN; Choudhury B; Moyle PM; Toth I; Batzloff MR; Good MF; Agarwal P; Kapoor N; Nizet V; Silvestri G; Walker MJ
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
    Layton RC; Gigliotti A; Armijo P; Myers L; Knight J; Donart N; Pyles J; Vaughan S; Plourde J; Fomukong N; Harrod KS; Gao P; Koster F
    PLoS One; 2011; 6(6):e20641. PubMed ID: 21687736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.
    Reynolds S; Pandey M; Dooley J; Calcutt A; Batzloff M; Ozberk V; Mills JL; Good M
    Sci Rep; 2021 Jan; 11(1):127. PubMed ID: 33420258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings.
    Davies C; Taba M; Deng L; Karatas C; Bag S; Ross C; Forster A; Booy R; Skinner SR
    Hum Vaccin Immunother; 2022 Nov; 18(4):2018863. PubMed ID: 35100525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine.
    Wijesundara DK; Yeow A; McMillan CLD; Choo JJY; Todorovic A; Mekonnen ZA; Masavuli MG; Young PR; Gowans EJ; Grubor-Bauk B; Muller DA
    Mol Ther Nucleic Acids; 2023 Dec; 34():102056. PubMed ID: 38028199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.
    Pandey M; Langshaw E; Hartas J; Lam A; Batzloff MR; Good MF
    J Immunol; 2015 Jun; 194(12):5915-25. PubMed ID: 25980008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.
    Hacker E; Baker B; Lake T; Ross C; Cox M; Davies C; Skinner SR; Booy R; Forster A
    Vaccine; 2023 Sep; 41(41):5925-5930. PubMed ID: 37643926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
    mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
    Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
    Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.